Sugi Predict

Sugi Predict / Compounds / SCHEMBL2298689

SCHEMBL2298689

SCHEMBL2298689

CC(C)(C)OC(=O)Nc1cc(N)ncn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ GSK3B P49841 1/20 0.42
▸ DYRK1A Q13627 1/20 0.42
▸ AAK1 Q2M2I8 2/20 0.40
▸ MKNK2 Q9HBH9 1/20 0.40
▸ PIK3CD O00329 2/20 0.39
▸ ABL1 P00519 2/20 0.39
▸ EGFR P00533 2/20 0.39
▸ KDR P35968 2/20 0.39
▸ PIK3CA P42336 2/20 0.39
▸ PIK3CG P48736 2/20 0.39
▸ PRKDC P78527 2/20 0.39
▸ BACE1 P56817 1/20 0.39
▸ PI4KB Q9UBF8 1/20 0.39
▸ CDK5 Q00535 2/20 0.39
▸ TAOK1 Q7L7X3 1/20 0.39
▸ CLK4 Q9HAZ1 1/20 0.39
▸ ATR Q13535 1/20 0.38
▸ CA1 P00915 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31430989 0.84 L3MBTL1 (0.47) MAP4K4L3MBTL1GSK3BDYRK1AAAK1
SCHEMBL18805591 0.83 ATR (0.45) MAP4K4L3MBTL1GSK3BDYRK1AAAK1
SCHEMBL29400652 0.83 ATR (0.45) MAP4K4L3MBTL1GSK3BDYRK1AAAK1
SCHEMBL18805592 0.83 L3MBTL1 (0.68) MAP4K4L3MBTL1GSK3BDYRK1AAAK1
SCHEMBL18814953 0.83 L3MBTL1 (0.49) MAP4K4L3MBTL1GSK3BDYRK1AAAK1
SCHEMBL19890987 0.83 L3MBTL1 (0.44) MAP4K4L3MBTL1GSK3BDYRK1AAAK1
SCHEMBL27910466 0.80 L3MBTL1 (0.44) L3MBTL1AAK1MKNK2EGFRKDR
SCHEMBL24834890 0.79 AAK1 (0.36) MAP4K4GSK3BDYRK1AAAK1MKNK2
SCHEMBL30161841 0.79 AAK1 (0.36) MAP4K4GSK3BDYRK1AAAK1MKNK2
SCHEMBL798703 0.79 L3MBTL1 (0.41) MAP4K4L3MBTL1GSK3BDYRK1AAAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092799-A1 MNK INHIBITORS HEPAGENE THERAPEUTICS HK LTD (CN) 2024-03-21 — — US disclosed
CN-111253397-B MNK inhibitors 上海迪诺医药科技有限公司 2023-11-14 — — CN disclosed
EP-3521289-B1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS INC (US) 2023-10-25 — — EP disclosed
CN-116490505-A MNK inhibitors 和博医药有限公司 2023-07-25 — — CN disclosed
EP-4200296-A1 MNK INHIBITORS Hepagene Therapeutics (HK) Limited (HK) 2023-06-28 — — EP disclosed
WO-2022038563-A1 MNK INHIBITORS Hepagene Therapeutics (HK) Limited (CN) 2022-02-24 — — WO disclosed
US-20210338673-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS INC (US) 2021-11-04 — — US disclosed
CN-111253397-A MNK inhibitors 上海迪诺医药科技有限公司 2020-06-09 — — CN disclosed
EP-3521289-A1 MNK INHIBITORS AND METHODS RELATED THERETO Effector Therapeutics Inc. (US) 2019-08-07 — — EP disclosed
US-20190209560-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS, INC. 2019-07-11 — — US disclosed
US-20150376181-A1 MNK INHIBITORS AND METHODS RELATED THERETO OXFORD FINANCE LLC, AS COLLATERAL AGENT 2015-12-31 — — US disclosed
US-20150376181-A1 MNK INHIBITORS AND METHODS RELATED THERETO OXFORD FINANCE LLC, AS COLLATERAL AGENT 2015-12-31 — — US disclosed
WO-2015200481-A1 MNK INHIBITORS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS, INC. (US) 2015-12-30 — — WO disclosed
CN-103097381-B As 1,8-naphthyridines material of kinase inhibitor MERCK PATENT GMBH (DE) 2015-10-07 — — CN disclosed
EP-2539336-B1 HETARYLAMINONAPHTHYRIDINES MERCK PATENT GMBH (DE) 2014-10-22 — — EP disclosed
US-8815893-B2 Hetarylaminonaphthyridines MERCK PATENT GMBH (DE) 2014-08-26 — — US disclosed
CN-103097381-A 1, 8-naphthyridines as kinase inhibitors MERCK PATENT GMBH 2013-05-08 — — CN disclosed
EP-2539336-A2 HETARYLAMINONAPHTHYRIDINES Merck Patent GmbH (DE) 2013-01-02 — — EP disclosed
US-20120316166-A1 HETARYLAMINONAPHTHYRIDINES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-12-13 — — US disclosed
WO-2011101069-A2 HETARYLAMINONAPHTHYRIDINES MERCK PATENT GMBH (DE) 2011-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376181-A1 MNK INHIBITORS AND METHODS RELATED THERETO TNNI3K, NIM1K, NEK9 MAP4K4 58/4885L3MBTL1 2801/4885GSK3B 267/4885
US-20240092799-A1 MNK INHIBITORS MKNK1, MATK, NEK1 MAP4K4 54/4885L3MBTL1 1524/4885GSK3B 1232/4885
US-20190209560-A1 MNK INHIBITORS AND METHODS RELATED THERETO TNNI3K, NIM1K, NEK9 MAP4K4 58/4885L3MBTL1 2801/4885GSK3B 267/4885
US-20210338673-A1 MNK INHIBITORS AND METHODS RELATED THERETO TNNI3K, NIM1K, NEK9 MAP4K4 58/4885L3MBTL1 2801/4885GSK3B 267/4885
US-20120316166-A1 HETARYLAMINONAPHTHYRIDINES ATP5ME, ATP5F1A, ATP5F1D MAP4K4 2697/4885L3MBTL1 980/4885GSK3B 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.